Remeron (mirtazapine)

Generic name: Mirtazapine Available strengths: 7.5 mg, 15 mg, 30 mg, 45 mg tablets; 15 mg, 30 mg, 45 mg quick-dissolving tablets (Remeron SolTab) Available in generic: Yes Drug class: Norepinephrine-serotonin modulator antidepressant

General Information

Remeron (mirtazapine) exerts its antidepressant action principally through antagonism of certain types of receptors, thereby altering neurotransmission of **serotonin** and **norepinephrine** in the brain. *Neurotransmitters*, such as serotonin and norepinephrine, are chemicals produced by brain cells called neurons that enable them to communicate with each other. The neurotransmitters are released by one neuron into the space between that neuron and the next neuron. The neurotransmitters come into contact with specific sites on the surface membrane of neurons called *receptors*. From there, the chemical signal is transformed into an electrical impulse that travels down the neuron, causing further release of neurotransmitters. This process of neurotransmission is repeated along a chain of neurons.

Depression and other mental disorders may be caused by abnormally low levels (or abnormal transmission) of serotonin, norepinephrine, or both. This abnormality may in turn produce changes in affected areas of the brain, resulting in psychiatric symptoms such as depression or anxiety. When neurotransmission is improved by the antidepressant, the affected areas of the brain are restored to normal functioning, reducing the symptoms of the illness. There is usually a time lag of 3–4 weeks for antidepressants to achieve their optimal effect, which may be the time needed for the brain to make the changes to restore previously affected areas to normal functioning, hence reducing or eliminating the symptoms of the illness.

Remeron was approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder. The use of a medication for its approved indications is called its *labeled use*. In clinical practice, however, physicians often prescribe medications for *unlabeled* ("off-label") uses when published clinical studies, case reports, or their own clinical experiences support the efficacy and safety of those treatments. Unlabeled uses of Remeron include treatment of anxiety disorders with or without depression, posttraumatic stress disorder, and insomnia.

Physicians may use Remeron in combination with a selective serotonin reuptake inhibitor (SSRI) such as Zoloft (sertraline) or Lexapro (escitalopram) to augment the antidepressant effect. This augmentation strategy may be successful in treating refractory depression for which the response to a single antidepressant was inadequate.

Dosing Information

The recommended starting dose is 15 mg, taken once a day, preferably in the evening prior to bedtime. After 1–2 weeks, the dosage may be increased in increments of 15 mg/day at intervals of 1–2 weeks up to a maximum of 45 mg/day. Remeron also comes in quick-dissolving tablets (Remeron SolTab) for ease of swallowing.

Common Side Effects

Remeron is usually well tolerated, and only infrequently is the medication stopped because of intolerable side effects. The most common side effects are dry mouth, drowsiness, sedation, and weight gain. Daytime sleep-iness may be managed by taking a single dose close to bedtime.

For some patients taking Remeron, increased appetite and weight gain may be problematic. About 20% of patients taking Remeron gain weight with long-term use. In addition, Remeron may have effects on cholesterol and triglycerides. Cholesterol may significantly increase in about 15%, and triglycerides in about 6%, of the patients taking Remeron. Management of weight gain is usually accomplished by controlling appetite and diet and through exercise. Cholesterol and triglyceride levels should be checked before and periodically (at least annually) during treatment with Remeron. Any patient with Remeron-induced weight gain should be monitored closely, especially if at risk for diabetes and heart disease.

Unlike SSRIs, Remeron rarely induces sexual dysfunction. It is a useful alternative to other antidepressants that produce sexual dysfunction.

Adverse Reactions and Precautions

Remeron may cause drowsiness in some people. Patients should not drive or operate machinery until they are certain that their alertness or coordination is not affected by the medication. Patients with a known allergy to Remeron or who have experienced a severe reaction after taking it should not take Remeron.

Use in Pregnancy and Breastfeeding: Pregnancy Category C

Remeron has not been tested in women to determine its safety in pregnancy. The effects of the medication on the developing fetus in pregnant women are unknown. Women who are pregnant or may become pregnant should discuss this with their physician. Some women may experience a recurrence of their depression when they stop their antidepressant. In these circumstances it may be necessary to restart the medication or seek an alternative medication or treatment.

Nursing mothers should not take Remeron, because small amounts will pass into breast milk and be ingested by the baby. If stopping the drug is not an alternative, breastfeeding should not be started or should be discontinued.

Possible Drug Interactions

Remeron, like many other medications, is metabolized in the liver. The combined use with certain medications may result in adverse drug interactions because one medication may alter the blood levels of the other. Fortunately, the number of reported drug interactions with Remeron is few. The significant drug interactions that have been reported with Remeron are summarized in the table below.

Tagamet (cimetidine)	Tagamet may increase the blood levels of Remeron, potentially causing side effects.
Tegretol (carbamazepine)	Tegretol reduces the blood levels of Remeron, possibly decreas- ing its antidepressant effects.
Luvox (fluvoxamine)	Luvox may significantly increase the blood levels of Remeron to toxic levels.

Other medications, including herbal supplements (such as St. John's wort), that boost serotonin may result in excessive levels of that neurotransmitter when combined with Remeron and produce a toxic syndrome known as **serotonin syndrome**. The early signs of serotonin syndrome are restlessness, confusion, tremors, flushing, and involuntary muscle jerks. If the medications are not stopped, the individual may develop more life-threatening complications resulting in muscle disorders, high fever, respiratory problems, clotting problems, and destruction of red blood cells that may lead to acute renal failure. Patients taking Remeron should be alert to the possible signs of serotonin syndrome, which require immediate medical attention and discontinuation of the serotonin-boosting medications.

Antidepressants known as **monoamine oxidase inhibitors** (MAOIs) should not be taken together with Remeron, because the combination may potentially produce a toxic reaction that includes elevated temperature, high blood pressure, and extreme excitation and agitation. Patients should consult their physician or pharmacist before taking any new medications, including over-the-counter medications and herbal supplements, with Remeron.

Patients taking Remeron should avoid alcohol or should consume it in moderation because the combination may worsen depression.

Overdose

Compared with some other antidepressants, such as tricyclic antidepressants, Remeron is relatively safe in overdose. However, when multiple medications are involved in overdose, the other medications may increase the risk of more serious complications.

Any suspected overdose should be treated as an emergency. The person should be taken to the emergency room for observation and treatment. The prescription bottle of medication (and any other medication suspected in the overdose) should be brought as well, because the information on the prescription label can be helpful to the treating physician in determining the number of pills ingested.

Special Considerations

Most cases of major depression can be treated successfully, usually with medication, psychotherapy, or both. The combination of psychotherapy and antidepressants is very effective in treating moderate to severe depression. The medications improve mood, sleep, energy, and appetite, while therapy strengthens coping skills, deals with possible underlying issues, and improves thought patterns and behavior.

In general, antidepressants alone help about 60%–70% of those taking them. Although a few individuals may experience some improvement from antidepressants by the end of the first week, most people do not see significant benefits from their antidepressants until after 3–4 weeks, and it can sometimes take as long as

8 weeks for the medication to produce its full effects. Thus it is critical that patients continue to take their antidepressant long enough for the medication to be beneficial and that patients not get discouraged and stop their medication prematurely if they do not feel better immediately.

In short-term studies, antidepressants were found to increase the risk of suicidal thinking and behavior in children and adolescents with major depression and other psychiatric disorders. The FDA requires the prescriber to warn of this risk in children and adolescents when starting antidepressant therapy. According to the FDA findings, the risk of suicidal thoughts and behaviors associated with antidepressants is age-related. This phenomenon tends to occur in the younger population and is most likely to occur early in the course of treatment. In adults over 24 years of age, there did not appear to be an increased risk of suicidality with anti-depressants compared with placebo. In patients over age 65, the findings showed that antidepressants had a "protective effect" against suicidal thoughts and behavior. Other studies have found that when more people in a community are taking antidepressants, the suicide rate is lower.

The risk of suicide is inherent in depression and may persist until the individual responds to treatment. After starting or changing antidepressant therapy, the person, especially a child or adolescent, should be closely observed for worsening signs of depression, and the family or caregiver should communicate any concerns to the physician.

- **Warning:** Always let your physician or a family member know if you have suicidal thoughts. Notify your psychiatrist or your family physician whenever your depressive symptoms worsen or whenever you feel unable to control suicidal urges or thoughts.
- Do not discontinue Remeron without consulting your physician.
- If you miss a dose, take it as soon as possible. If it is close to the next scheduled dose, skip the missed dose and continue on your regular dosing schedule. Do not take double doses.
- Remeron may be taken with or without food.
- Store the medication in its originally labeled, light-resistant container, away from heat and moisture. Heat and moisture may precipitate breakdown of your medication, and the medication may lose its therapeutic effects.
- Keep your medication out of reach of children.

If you have any questions about your medication, consult your physician or pharmacist.

Notes

Copyright © **2009 American Psychiatric Publishing, Inc.** The purchaser of this book is licensed to distribute copies of these handouts in limited amounts. Please see copyright page for further information. The authors have worked to ensure that all information on this handout concerning drug dosages, schedules, routes of administration, and side effects is accurate as of the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community and accepted psychiatric practice. This handout does not cover all possible uses, precautions, side effects, or interactions of the drug. For a complete listing of side effects, see the manufacturer's package insert, which can be obtained from your physician or pharmacist. As medical research and practice advance, therapeutic standards may change. For this reason, and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of a physician who is directly involved in their care or the care of a member of their family.

From Chew RH, Hales RE, Yudofsky SC: What Your Patients Need to Know About Psychiatric Medications, Second Edition. Washington, DC, American Psychiatric Publishing, 2009